|
Anna Sureda MD, PhD
Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme
Institut Català d'Oncologia - Hospital Duran i Reynals (Barcelona)
Spain
|
Anna Sureda, (MD, PhD) is nowadays the Head of the Clinical Hematology Department of Institut Català
d’Oncologia – Hospitalet, Barcelona. She had previously been a Senior Consultant in Hospital de la Santa
Creu i Sant Pau, Barcelona (from January 1991 to December 2010) and a Senior Consultant focused in
lymphomas and hematopoietic stem cell transplantation (HSCT) at Addenbrookes–Cambridge University
Hospital, UK (December 2010 – December 2012). Anna Sureda has focused her career on clinical
investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma
patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Anna
Sureda was appointed Chairperson of the Lymphoma Working Party (LWP) of the European Group for
Blood and Marrow Transplantation (EBMT) from March 2004 to March 2010 and Secretary of the same
organization from March 2010 to March 2016. She was elected co-chair of the Lymphoma Committee of
the Center for International Blood and Marrow Transplant Research (CIBMTR) and has served the
organization in this position from February 2015 to February 2019. She was subsequently appointed as
member of a large non-US Transplant Center in the Advisory Committee of the CIBMTR (from February
2019). Anna Sureda is President of the Spanish Society of Hematopoietic Stem Cell Transplantation and
Cellular Therapy (GETH-TC) and, from March 2022, President of the EBMT. Anna Sureda is regular
reviewer of several peer reviewed journals (Blood, Annals of Oncology, Bone Marrow Transplantation, The
Hematology Journal, The European Journal of Hematology y Annals of Hematology) and has co-authored
more than 400 manuscripts.
d’Oncologia – Hospitalet, Barcelona. She had previously been a Senior Consultant in Hospital de la Santa
Creu i Sant Pau, Barcelona (from January 1991 to December 2010) and a Senior Consultant focused in
lymphomas and hematopoietic stem cell transplantation (HSCT) at Addenbrookes–Cambridge University
Hospital, UK (December 2010 – December 2012). Anna Sureda has focused her career on clinical
investigations into the treatment of Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma
patients evaluating novel therapies such as immunotherapy combined with stem-cell transplantation. Anna
Sureda was appointed Chairperson of the Lymphoma Working Party (LWP) of the European Group for
Blood and Marrow Transplantation (EBMT) from March 2004 to March 2010 and Secretary of the same
organization from March 2010 to March 2016. She was elected co-chair of the Lymphoma Committee of
the Center for International Blood and Marrow Transplant Research (CIBMTR) and has served the
organization in this position from February 2015 to February 2019. She was subsequently appointed as
member of a large non-US Transplant Center in the Advisory Committee of the CIBMTR (from February
2019). Anna Sureda is President of the Spanish Society of Hematopoietic Stem Cell Transplantation and
Cellular Therapy (GETH-TC) and, from March 2022, President of the EBMT. Anna Sureda is regular
reviewer of several peer reviewed journals (Blood, Annals of Oncology, Bone Marrow Transplantation, The
Hematology Journal, The European Journal of Hematology y Annals of Hematology) and has co-authored
more than 400 manuscripts.